The agency based its decision on results from the Phase III ALINA trial in which Alecensa improved disease-free survival in ALK-positive NSCLC patients.

The babies were treated before symptom onset, and are sitting, standing, and walking independently, many consistent with ...

Sanofi is putting down $18 million across three historically Black medical schools as part of the French pharma's efforts to ...

Swiss drug makers Lonza and Roche agreed in March to the sale the Vacaville campus in the heart of Solano County’s burgeoning ...

Distinct immune "signatures" in patients who develop adverse events while taking immunotherapy for cancer may help oncologists identify patients at risk and treat them early to prevent serious side ...

And in September 2023, Genentech, a Member of the Roche Group, committed $47 million upfront, and potentially up-to-$2 billion-plus in milestone payments toward developing small molecule molecular ...

Glaub and Ford worked together at Afferent Pharmaceuticals Inc., where Glaub was CEO and Ford chief scientific officer. Their ...

Distinct immune 'signatures' in patients who develop adverse events while taking immunotherapy for cancer may help oncologists identify patients at risk and treat them early to prevent serious side ...

The long-term risk of distant recurrence for women with early breast cancer has declined significantly, a decades-long ...

Distinct immune “signatures” in patients who develop adverse events while taking immunotherapy for cancer may help ...

With positive results for patients with the chronic skin condition, Jasper Therapeutics’ briquilimab is looking to take on ...

Just in the first half of 2024, over $1.7 billion was committed to autoimmune disease research. The influx is driven largely ...